Showing 2811-2820 of 5909 results for "".
- SightGlass Vision Announces R&D Webinar Featuring Leading Myopia Expertshttps://modernod.com/news/sightglass-vision-announces-rd-webinar-featuring-leading-myopia-experts/2477704/SightGlass Vision announced it will hold an R&D webinar to discuss the science of and latest research in myopia, as well as provide an overview about the clinical development and commercialization program for the company’s novel glasses designed to slow the progression of myopia in chil
- CooperVision Extends Deadline for Science and Technology Awards Proposalshttps://modernod.com/news/coopervision-extends-deadline-for-science-and-technology-awards-proposals/2477688/CooperVision has extended the submission deadline for its
- AAO, ASCRS, and OOSS Develop Checklist for Reopening Ophthalmic Surgery Centershttps://modernod.com/news/ooss-aao-and-ascrs-develop-checklist-for-reopening-ophthalmic-surgery-centers/2477669/To support the safe reopening of care, the American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), and the Outpatient Ophthalmic Surgery Society (OOSS), developed a checklist<
- European Leaders, WHO Team Up on $8 Billion Pandemic Vaccine Responsehttps://modernod.com/news/european-leaders-who-team-up-on-8b-pandemic-vaccine-response/2477664/The leaders of Germany and France and a host of other EU countries and groups have come together with the World Health Organization (WHO) for an $8 billion push for a new vaccine against COVID-19, according to a FierceBiotech
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeuticshttps://modernod.com/news/q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics/2477631/Q BioMed announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. This novel drug program is being evaluated by government pro
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- Leo Lens Pharma Appoints Dan Myers CEOhttps://modernod.com/news/leo-lens-pharma-appoints-dan-myers-ceo/2477589/Leo Lens Pharma has announced the appointment of Dan Myers as Chief Executive Officer. Prior to joining Leo Lens, Mr. Myers was the co-founder and Chief Executive Officer of Alimera Sciences, where he continues to serve as chairman of the Board of Directors. Before founding Alimera, Mr. Myers was
- FDA Quickly Authorizes Its 2nd Blood Filtering Device for COVID-19https://modernod.com/news/fda-quickly-authorizes-its-2nd-blood-filtering-device-for-covid-19/2477585/Shortly after granting an emergency authorization to Terumo BCT’s blood filtering device for COVID-19, the FDA did the same for CytoSorbents’ system, according to a FierceBiotech